<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Leeuwen, F.W. van</title>
    <link>http://repub.eur.nl/res/aut/9342/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Dose-dependent inhibition of proteasome activity by a mutant ubiquitin associated with neurodegenerative disease (Article)</title>
      <link>http://repub.eur.nl/res/pub/35443/</link>
      <pubDate>2007-05-01T00:00:00Z</pubDate>
      <description>The ubiquitin-proteasome system is the main regulated intracellular proteolytic pathway. Increasing evidence implicates impairment of this system in the pathogenesis of diseases with ubiquitin-positive pathology. A mutant ubiquitin, UBB+1, accumulates in the pathological hallmarks of tauopathies, including Alzheimer's disease, polyglutamine diseases, liver disease and muscle disease and serves as an endogenous reporter for proteasomal dysfunction in these diseases. UBB+1is a substrate for proteasomal degradation, however it can also inhibit the proteasome. Here, we show that UBB+1properties shift from substrate to inhibitor in a dose-dependent manner in cell culture using an inducible UBB+1expression system. At low expression levels, UBB+1was efficiently degraded by the proteasome. At high levels, the proteasome failed to degrade UBB+1, causing its accumulation, which subsequently induced a reversible functional impairment of the ubiquitin-proteasome system. Also in brain slice cultures, UBB+1accumulation and concomitant proteasome inhibition was only induced at high expression levels. Our findings show that by varying UBB+1expression levels, the dual proteasome substrate and inhibitory properties can be optimally used to serve as a research tool to study the ubiquitin-proteasome system and to further elucidate the role of aberrations of this pathway in disease.</description>
    </item> <item>
      <title>Frameshift mutants of β amyloid precursor protein and ubiquitin-B are prominent in Alzheimer and Down patients. (Article)</title>
      <link>http://repub.eur.nl/res/pub/2556/</link>
      <pubDate>1998-01-09T00:00:00Z</pubDate>
      <description>The cerebral cortex of Alzheimer's and Down syndrome patients is characterized by the presence of protein deposits in neurofibrillary tangles, neuritic plaques, and neuropil threads. These structures were shown to contain forms of beta  amyloid precursor protein and ubiquitin-B that are aberrant (+1 proteins) in the carboxyl terminus. The +1 proteins were not found in young control patients, whereas the presence of ubiquitin-B+1 in elderly control patients may indicate early stages of neurodegeneration. The two species of +1 proteins displayed cellular colocalization, suggesting a common origin, operating at the transcriptional level or by posttranscriptional editing of RNA. This type of transcript mutation is likely an important factor in the widely occurring nonfamilial early- and late-onset forms of Alzheimer's disease.</description>
    </item>
  </channel>
</rss>